Intraductally administered pegylated liposomal doxorubicin reduces mammary stem cell function in the mammary gland but in the long term, induces malignant tumors

Breast Cancer Research and Treatment

Volumn 135, Issue 1, 2012, Pages 201-208

  Chun, Yong Soon ^a,b   Yoshida, Takahiro ^a   Mori, Tsuyoshi ^a,c   Huso, David L ^a   Zhang, Zhe ^a   Stearns, Vered ^a   Perkins, Brandy ^a   Jones, Richard J ^a   Sukumar, Saraswati ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Gachon University   (South Korea)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Carcinogenesis; Doxorubicin; Intraductal; Mammary; Stem cell

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER STEM CELL; CELL FUNCTION; CELL POPULATION; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; DRUG METABOLISM; DRUG SAFETY; EPITHELIUM CELL; FEMALE; INTRADUCTAL DRUG ADMINISTRATION; LONG TERM CARE; MALIGNANT TRANSFORMATION; MAMMARY GLAND FUNCTION; MILK PRODUCTION; MOUSE; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; FEMALE; LACTATION; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; POLYETHYLENE GLYCOLS; PREGNANCY; STEM CELLS;

EID: 84865150214     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2138-x     Document Type: Article

References (20)

1. Molofsky AV, Pardal R, Morrison SJ (2004) Diverse mechanisms regulate stem cell self-renewal. Curr Opin Cell Biol 16:700-707 (Pubitemid 39467731)
2. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer and cancer stem cells. Nature 414:105-111 (Pubitemid 33041634)
3. Perryman SV, Sylvester KG (2006) Repair and regeneration opportunities for carcinogenesis from tissue stem cells. J Cell Mol Med 10:292-308 (Pubitemid 44870180)
4. Smith GH (2005) Stem cells and mammary cancer in mice. Stem Cell Rev 1:215-223 (Pubitemid 41737098)
5. Williams JM, Daniel CW (1983) Mammary ductal elongation: differentiation of myoepithelium and basal lamina during branching morphogenesis. Dev Biol 97:274-290 (Pubitemid 13029836)
6. Smith GH, Chepko G (2001) Mammary epithelial stem cells. Microsc Res Tech 15:190-203 (Pubitemid 32107807)
7. Murata S, Kominsky SL, Vali M, Zhang Z, Garrett-Mayer E, Korz D, Huso D, Baker SD, Barber J, Jaffee E, Reilly RT, Sukumar S (2006) Ductal access for prevention and therapy of mammary tumors. Cancer Res 66:638-645 (Pubitemid 43165923)
8. Stearns V, Mori T, Jacobs LK, Khouri NF, Gabrielson E, Yoshida T, Kominsky SL, Huso DL, Jeter S, Powers P, Tarpinian K, Brown RJ, Lange JR, Rudek MA, Zhang Z, Tsangaris TN, Sukumar S (2011) Preclinical and clinical evaluation of intraductally administered agents in early breast cancer. Sci Transl Med 3(106):106ra108
9. Stingl J, Eirew P, Ricketson I, Shackleton M, Vailant F, Choi D, Li HI, Eaves CJ (2006) Purification and unique properties of mammary epithelial stem cells. Nature 439:993-997 (Pubitemid 43292419)
10. Shackleton M, Vailant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, Visvader JE (2006) Generation of functional mammary gland from a single stem cell. Nature 439:84-88 (Pubitemid 43053633)
11. Atabai K, Fernandez R, Huang X, Ueki I, Kline A, Li Y, Sadatmansoori S, Smith-Steinhart C, Zhu W, Pytela R, Werb Z, Sheppard D (2005) Mfge8 is critical for mammary gland remodeling during involution. Mol Biol Cell 16(12):5528-5537 (Pubitemid 41752204)
12. Liu S, Liu W, Jakubczak JL, Erexson GL, Tindall KR, Chan R, Muller WJ, Adhya S, Garges S, Merlino G (2002) Genetic instability favoring transversions associated with ErbB2-induced mammary tumorigenesis. Proc Natl Acad Sci USA 99(6):3770-3775 (Pubitemid 34252181)
13. Gabizon AA (2001) Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 19:424-436 (Pubitemid 32525189)
14. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA (1994) Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol 45:649-656 (Pubitemid 24139191)
15. Rieche K (1984) Carcinogenicity of antineoplastic agents in man. Cancer Treat Rev 11:39-67 (Pubitemid 16017947)
16. Bertazzoli C, Chieli T, Solcia E (1971) Different incidence of breast carcinomas or fibroadenomas in daunomycin or adriamycin treated rats. Experientia 27(10):1029-1036
17. Bucciarelli E (1981) Mammary tumor induction in male and female Sprague-Dawley rats by adriamycin and daunomycin. J Natl Cancer Inst 66:81-84 (Pubitemid 11163238)
18. Solcia E, Ballerini L, Ballini O, Sala L, Bertazzoli C (1978) Mammary tumors induced in rats by Adriamycin and Daunomycin. Cancer Res 38:1444-1446 (Pubitemid 8324630)
19. Howell SK, Stephens LC, Wang YM (1989) Daunorubicin-induced mammary tumors in the rat. Eur J Cancer Clin Oncol 25:1549-1554 (Pubitemid 20002427)
20. Jacobs L, Sukumar S, Stearns S (2010) Intraductal therapy for the prevention of breast cancer. Curr Opin Investig Drugs 11(6):646-652